BioSight

BioSight's lead candidate is BST-236, a cytarabine-based prodrug in clinical development for acute myeloid leukemia. It is designed to deliver high-dose chemotherapy directly to cancer cells while sparing healthy tissue, potentially allowing older or unfit patients to receive intensive treatment they otherwise could not tolerate. The firm's website presents BST-236 as its sole disclosed pipeline asset.

No other drug candidates are disclosed on BioSight's website as of the latest available information. The firm's public corporate profile is built entirely around the advancement of BST-236, positioning it as a single-asset pharmaceutical developer.

BioSight's operations are based in Israel, with its website listing Herzliya, Rehovot, Petach Tikva, and Lod. It also mentions locations in Malvern, Houston, Oakland, and Givatayim, which may indicate associated corporate, clinical, or regulatory activities in the United States, though these are not detailed.

BioSight does not publicly identify its founders, management team, or board of directors on its primary website. The firm operates without a public-facing executive leadership page, making the identity of key investment and scientific decision-makers unavailable from primary sources.

BioSight is a pharmaceutical development company, not an investment fund, and does not deploy capital into external portfolio companies or participate in venture funding rounds. Allocation to BioSight would occur via direct equity investment in the company or through an undisclosed venture capital backer, neither of which is publicly detailed.